One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Comparative Risk of Angioedema With Sacubitril-Valsartan vs Renin-Angiotensin-Aldosterone Inhibitors
Efe Eworuke, PH D, a Emily C. Welch, MPH,b Nicole Haug, MPH,b Casie Horgan, MPH, b Hye Seung Lee, PH D, c Yueqin Zhao, PH D, c Ting-Ying Huang, PHD
doi : 10.1016/j.jacc.2022.10.033
Volume 81, Issue 4, 31 January 2023, Pages 321-331
Data on angioedema risk among sacubitril-valsartan (SV) users in real-world settings are limited.
The Real-World Price of Switching to an ARNI: A Case for De Novo Sacubitril/Valsartan Initiation∗
Robert L. Page II, P HARMD, MSPH
doi : 10.1016/j.jacc.2022.11.024
Volume 81, Issue 4, 31 January 2023, Pages 332-335
Somatostatin Receptor PET/MR Imaging of Inflammation in Patients With Large Vessel Vasculitis and Atherosclerosis
Andrej Corovic, MB BC HIR,a Christopher Wall, MB BC HIR,a Meritxell Nus, PH D, a Deepa Gopalan, MBBS, b,c Yuan Huang, P HD, d Maria Imaz, BS,a Michal Zulcinski, MS,e Marta Peverelli, MD,a,f Anna Uryga, PH D, a Jordi Lambert, PHD, a Dario Bressan, PHD, g Robert T. Maughan, P HD, f Charis Pericleous, P HD, f Suraiya Dubash, MD, P HD, h,i Natasha Jordan, MD,j David R. Jayne, MD, P HD, k Stephen P. Hoole, DM,l Patrick A. Calvert, MD, PHD, l Andrew F. Dean, MD, m Doris Rassl, MD, n Tara Barwick, MD, b,i Mark Iles, PHD, e Mattia Frontini, PHD, o Greg Hannon, PHD, g Roido Manavaki, PHD, p Tim D. Fryer, PH D, q Luigi Aloj, MD, p Martin J. Graves, P HD, p Fiona J. Gilbert, MD, P HD, p Marc R. Dweck, MD, PH D, r David E. Newby, MD, PHD, r Zahi A. Fayad, P HD, s Gary Reynolds, MD, PHD, t Ann W. Morgan, MD, PHD, e Eric O. Aboagye, MD, P HD, i Anthony P. Davenport, P HD, a Helle F. Jørgensen, PH D, a Ziad Mallat, MD, PHD, a Martin R. Bennett, MD, PHD, a James E. Peters, MD, PHD, u James H.F. Rudd, MD, P HD, a Justin C. Mason, MD, P HD, f Jason M. Tarkin, MBBS, P HD
doi : 10.1016/j.jacc.2022.10.034
Volume 81, Issue 4, 31 January 2023, Pages 336-354
Assessing inflammatory disease activity in large vessel vasculitis (LVV) can be challenging by conventional measures.
Somatostatin Receptor 2–Targeted PET Radiotracers Shine in Assessing Inflammatory Activity in Large Vessel Vasculitis∗
Ahmed Tawakol, MD, a,b Michael T. Osborne, MD
doi : 10.1016/j.jacc.2022.10.035
Volume 81, Issue 4, 31 January 2023, Pages 355-357
Revascularization Strategies for Patients With Femoropopliteal Peripheral Artery Disease
Serdar Farhan, MD, a Florian K. Enzmann, MD, PH D, b Patrick Bjorkman, MD, c Haroon Kamran, MD,a Zhongjie Zhang, MPH,a Samantha Sartori, PHD, a Birgit Vogel, MD,a Arthur Tarricone, DPM, a Klaus Linni, MD, d Maarit Venermo, MD,c Daphne van der Veen, e Herve Moussalli, MD,d Roxana Mehran, MD, a Michel M.P.J. Reijnen, MD, P HD, e,f Marc Bosiers, MD,g Prakash Krishnan, MD
doi : 10.1016/j.jacc.2022.10.036
Volume 81, Issue 4, 31 January 2023, Pages 358-370
No adequately powered studies exist to compare major clinical outcomes after endovascular therapy (EVT) with stent implantation vs bypass surgery (BSx) for symptomatic femoropopliteal peripheral artery disease.
Tradeoffs in Approach to PAD Revascularization: Shared Decision Making in the Spotlight∗
Marc P. Bonaca, MD, MPH,a,b,c Shea E. Hogan, MD, MSCS
doi : 10.1016/j.jacc.2022.11.030
Volume 81, Issue 4, 31 January 2023, Pages 371-373
Thromboprophylaxis in Patients With Fontan Circulation
Jef Van den Eynde, BS C, a,b, * Mathias Possner, MD, c,d, * Fares Alahdab, MD, MSC ,e Gruschen Veldtman, MBBS, f Bryan H. Goldstein, MD,g Rahul H. Rathod, MD, h Arvind K. Hoskoppal, MD, g Anita Saraf, MD, g Brian Feingold, MD, MS, g Tarek Alsaied, MD, MSC
doi : 10.1016/j.jacc.2022.10.037
Volume 81, Issue 4, 31 January 2023, Pages 374-389
The optimal strategy for thromboprophylaxis in patients with a Fontan circulation is unknown.
Thromboprophylaxis in the Fontan Circulation: Long-Awaited Validatio
Jeannette Lin, MD, Gentian Lluri, MD, PHD
doi : 10.1016/j.jacc.2022.11.029
Volume 81, Issue 4, 31 January 2023, Pages 390-393
Infective Endocarditis After Transcatheter Aortic Valve Replacement: JACC State-of-the-Art Review
David del Val, MD, P HD, a,b,c Vassili Panagides, MD,c Carlos A. Mestres, MD, PHD, d José M. Miró, MD, PHD, e,f Josep Rodés-Cabau, MD, PH D
doi : 10.1016/j.jacc.2022.11.028
Volume 81, Issue 4, 31 January 2023, Pages 394-412
Infective endocarditis (IE) is a rare but serious complication following transcatheter aortic valve replacement (TAVR).
Worsening Heart Failure: Nomenclature, Epidemiology, and Future Directions: JACC Review Topic of the Week
Stephen J. Greene, MD,a,b Johann Bauersachs, MD, c Jasper J. Brugts, MD, MSC, PHD, d Justin A. Ezekowitz, MBBC H, MS C,e Carolyn S.P. Lam, MBBS, PHD, f Lars H. Lund, MD, P HD, g Piotr Ponikowski, MD, PHD, h Adriaan A. Voors, MD, P HD, i Faiez Zannad, MD, PHD, j,k Shelley Zieroth, MD,l Javed Butler, MD, MPH, MBA
doi : 10.1016/j.jacc.2022.11.023
Volume 81, Issue 4, 31 January 2023, Pages 413-424
Heart failure (HF) is a progressive disease characterized by variable durations of symptomatic stability often punctuated by episodes of worsening despite continued therapy.
In Memoriam: Barry Zaret—A Life Well Lived, A Guiding Beacon, A Paragon to Follow
Jeffrey Leppo, MD, a H. William Strauss, MD,b Jagat Narula, MD, P HD
doi : 10.1016/j.jacc.2022.12.009
Volume 81, Issue 4, 31 January 2023, Pages 425-427
Temporal Trends in Gender of Principal Investigators and Patients in Cardiovascular Clinical Trials
Celina Yong, MD, MBA, MSc Aashna Suvarna, BS Robert Harrington, MD Santosh Gummidipundi, MS Harlan M. Krumholz, MD, SM Roxana Mehran, MD Paul Heidenreich, MD, MS
doi : 10.1016/j.jacc.2022.10.038
Volume 81, Issue 4, 31 January 2023, Pages 428-430
